The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) announced this morning that the company’s wholly-owned subsidiary, Medican Organic Inc. has received its cultivation license from Health Canada for the Company’s breeding facility in Quebec.
The 72-acre land will allow the Medical Organic to produce proprietary, organically grown varieties of cannabis seeds and cannabis plants. The company started construction of its 820,000 sq. ft. hybrid grow facility earlier this year which will be able to product 116,000 kg’s of organically grown cannabis to consumers in the medical and recreational Canadian market.
The Green Organic Dutchman plans to engage in genetic breeding processes in order to create specific cannabinoid profiles that can be used in products that can be developed and patented. One of the issues facing the cannabis industry is the lack of consistency within products developed on the market. Through trial and error the company hopes to able to create product that is dependable and cultivate high yielding cannabinoid varieties that produce strains rich in CBD, CBG, GBC, and THCV.
TGOD’s Vice President David Bernard-Perron gave this statement in the press release:
“One of the biggest gaps in the cannabis industry is the stabilization of genetics through modern breeding techniques, a process that is carried out with most agricultural crops. TGOD’s breeding facility will implement marker-assisted selective breeding to improve traits in cannabis, such as disease resistance to reduce the industry need to rely on pesticides. Improving the plant architecture and flower structure will allow for better mechanization of the harvesting process.”
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…